Business Context and Reporting Period
This Form 8-K was filed by Zentalis Pharmaceuticals, Inc. on May 20, 2022. The report addresses a corporate governance matter regarding the company's listing status on The Nasdaq Global Market.
Key Financial Metrics
This filing does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material change reported is a failure to satisfy a continued listing rule:
- Event: On May 18, 2022, Director Karan S. Takhar ceased serving on the Audit Committee.
- Impact: This resulted in noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires a minimum of three independent directors on the Audit Committee.
- Notification: The company received formal notification of this noncompliance from Nasdaq on May 20, 2022.
Outlook, Risks, and Management Commentary
Cure Period: Under Nasdaq Listing Rule 5605(c)(4), the company has been granted a cure period of 180 days to regain compliance, expiring on November 16, 2022.
Management Plan: The company intends to appoint a third independent director to the Audit Committee prior to the end of the cure period to resolve the noncompliance.
Risks: Failure to regain compliance by the deadline could result in delisting from The Nasdaq Global Market.
Investor Verification Checklist
- Verify the current composition of the Audit Committee to confirm if a third independent director has been appointed.
- Monitor future filings to ensure the company regains compliance before the November 16, 2022 deadline.
- Check for any subsequent communications from Nasdaq regarding the status of the cure period.